133 Castlereagh Street Sydney NSW
A driving force in the medical cannabis industry, Cann Global distributes medicinal cannabis and all-natural hemp food products to consumers all over the world.
They work under legislative provision to create an industry that allows medical practitioners, patients and consumers to be equipped with the right information, with access available to the safest, most effective and sustainable products. They were listed on the Australian Securities Exchange in 2008.
Whether for medicinal cannabis or for their health food range, Cann Global strives to provide high quality, plant-based products that are chemical free and sustainably grown. Their group is made up of three separate divisions – medical cannabis manufacturing, medical cannabis research and all-natural foods.
Their focus is the legal growth and cultivation of hemp to research and develop medicinal cannabis products to meet increasing demand both locally and globally.
For their medical cannabis division, Cann Global aims to grow cannabis research cultivation and cannabinoid-based agent production to develop, register and commercialise pharmaceutical grade cannabinoid-therapies, products and treatments to GMP quality standards. With a lawful unique seedbank developed and enhanced over 15 years in Australia, they are licensed to possess, cultivate, process, manufacture and supply cannabis.
As for Cann Global’s hemp food division, they work with the government in the development of trade and industry standards and in developing the branding of national hemp foods standards. They also manufacture, process and distribute a wide range of hemp food products.
For more information, Cann Global can be contacted by email at [email protected] or phoned at 02 8379 1832. Their correspondence address is at Level 21, 133 Castlereagh Street, Sydney, NSW 2000.
Industry: Medical Cannabis
Sub Industry: Hemp,CBD Oil,Cannabis Processor,Researcher,ASX-Listed
Products: Dried Cannabis Flower, Full Extract Oil, Hemp Foods
About (30 words): Cann Global (ASX:CGB) has business in industrial hemp and medicinal cannabis with plans to produce a range of cannabis products.